A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared With Placebo in Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
- NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
- NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
調査の概要
詳細な説明
The SAPPHIRE Clinical Trial
The Sponsor may in the future, through a protocol amendment, expand the protocol to include participants with idiopathic hypersomnia (IH) in Cohort C.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Centessa Pharmaceuticals
- 電話番号:617-468-5770
- メール:ORX750trials@centessa.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35213
- 募集
- Birmingham, Alabama
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80918
- 募集
- Colorado Springs, Colorado
-
-
Florida
-
Brandon、Florida、アメリカ、33511
- 募集
- Brandon, Florida
-
Miami、Florida、アメリカ、33155
- 募集
- Miami, Florida
-
Miami、Florida、アメリカ、33176
- 募集
- Miami, Florida
-
Miami、Florida、アメリカ、33166
- 募集
- Miami, Florida
-
Miami、Florida、アメリカ、33186
- 募集
- Miami, Florida
-
Miami Lakes、Florida、アメリカ、33014
- 募集
- Miami Lakes, Florida
-
Orlando、Florida、アメリカ、32807
- 募集
- Orlando, Florida
-
St. Petersburg、Florida、アメリカ、33707
- 募集
- St. Petersburg, Florida
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30328
- 募集
- Atlanta, Georgia
-
Rincon、Georgia、アメリカ、31326
- 募集
- Rincon, Georgia
-
Stockbridge、Georgia、アメリカ、30281
- 募集
- Stockbridge, Georgia
-
-
Michigan
-
Lansing、Michigan、アメリカ、48911
- 募集
- Lansing, Michigan
-
-
Mississippi
-
Flowood、Mississippi、アメリカ、39232
- 募集
- Flowood Mississippi
-
-
North Carolina
-
Denver、North Carolina、アメリカ、28037
- 募集
- Denver, North Carolina
-
Huntersville、North Carolina、アメリカ、28078
- 募集
- Huntersville, North Carolina
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45245
- 募集
- Cincinnati, Ohio
-
Dublin、Ohio、アメリカ、43017
- 募集
- Dublin, Ohio
-
-
South Carolina
-
Columbia、South Carolina、アメリカ、29201
- 募集
- Columbia, South Carolina
-
-
Texas
-
Austin、Texas、アメリカ、78731
- 募集
- Austin, Texas
-
Dallas、Texas、アメリカ、75251
- 募集
- Dallas, Texas
-
Frisco、Texas、アメリカ、75033
- 募集
- Frisco, Texas
-
Houston、Texas、アメリカ、77070
- 募集
- Houston, Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- San Antonio, Texas
-
Sugar Land、Texas、アメリカ、77478
- 募集
- Sugar Land, Texas
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- 18-70 years of age
- Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m^2 (inclusive)
- Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
- Is willing and able to discontinue all medications used for the treatment of narcolepsy
- Is willing and able to adhere to additional protocol requirements
Key Exclusion Criteria:
- Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
- Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group A - Narcolepsy Type 1 (Dose 1)
|
Oral cleminorexton capsule |
|
実験的:Group A - Narcolepsy Type 1 (Dose 2)
|
Oral cleminorexton capsule |
|
プラセボコンパレーター:Group A - Narcolepsy Type 1 (placebo)
|
matching placebo capsule |
|
実験的:Group B - Narcolepsy Type 2 (Dose 1)
|
Oral cleminorexton capsule |
|
実験的:Group B - Narcolepsy Type 2 (Dose 2)
|
Oral cleminorexton capsule |
|
プラセボコンパレーター:Group B - Narcolepsy Type 2 (placebo)
|
matching placebo capsule |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)
時間枠:Baseline to week 12
|
Baseline to week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Incidence, Severity, and casual relationship of participants with Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in clinical laboratory tests
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in vital signs
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with abnormal changes from baseline in 12-lead electrocardiograms (ECGs)
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Number of participants with at least 1 endorsement of Item 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Cmax: Maximum observed plasma concentration
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Tmax: Time of Maximum Concentration for cleminorexton
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
AUC: Area under the plasma concentration-time curve
時間枠:Baseline to Week 12
|
Baseline to Week 12
|
|
|
Weekly Cataplexy Rate (WCR)
時間枠:Week 12
|
Measurement specific to Group A |
Week 12
|
|
Change from baseline in Narcolepsy Severity Scale for Clinical Trials (NSS-CT)
時間枠:Baseline to Week 12
|
Measurement specific to Group A |
Baseline to Week 12
|
|
Change from baseline in Narcolepsy Severity Scale-2 for Clinical Trials (NSS2-CT) total score
時間枠:Baseline to Week 12
|
Measurement specific to Group B |
Baseline to Week 12
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- ORX750-004
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。